Skip to main content

Table 3 Descriptive statistics for quantitative assessments at baseline and after six months

From: The impact of respite care from the perspectives and experiences of people with amyotrophic lateral sclerosis and their care partners: a qualitative study

CONTROL GROUP

People with ALS (N = 14)

 

Time 1 (baseline)

Time 2 (after six months)

Assessment

N

Mean

St Dev

Range

N

Mean

St Dev

Range

ALSFRS-R

13

34.2

6.6

23–44

8

26.1

8.5

12–37

ECAS

12

104.1

12.6

82–120

5

114.4

7.5

108–127

GAD-7

13

3.3

5.1

0–15

8

2.3

4.1

0–11

MQOL-R

13

6.2

0.7

5.2–7.8

8

5.8

0.6

4.6–6.6

PHQ-9

13

6.5

3.9

0–12

8

5.4

4.3

1–15

Care Partners (N = 14)

 

Time 1 (baseline)

Time 2 (after six months)

Assessment

N

Mean

St Dev

Range

N

Mean

St Dev

Range

Adapted SSLI

13

14.7

3.8

10–23

9

15.3

2.4

12–19

ECAS – Section B

13

1.4

1.5

0–5

9

1.1

1.5

0–4

GAD-7

12

6.6

5.3

0–18

10

6.5

4.4

1–15

PHQ-9

13

6.8

6.0

0–19

10

7.6

6.1

1–19

QOLLTI-F v2

13

5.6

1.1

3.9–7.6

10

6.0

0.5

4.7–6.6

Relationship Closeness Scale

13

16.0

2.2

13–19

10

16.5

1.8

13–19

ZBI

13

34.6

16.3

9–56

10

33.4

14.0

7–51

RESPITE CARE GROUP

People with ALS (N = 17)

 

Time 1 (baseline)

Time 2 (after six months)

Assessment

N

Mean

St Dev

Range

N

Mean

St Dev

Range

ALSFRS-R

17

29.5

6.9

8–37

12

26.0

9.5

11–41

ECAS

16

99.2

16.4

61–121

8

104.6

12.2

79–118

GAD-7

17

5.1

5.8

0–19

12

3.3

2.9

0–9

MQOL-R

17

6.4

1.3

4.5–9.1

12

6.5

0.8

5.2–7.7

PHQ-9

17

6.5

6.4

0–20

12

5.3

4.1

0–14

Care Partners (N = 17)

Assessment

Time 1 (baseline)

Time 2 (after 6 months)

 

N

Mean

St Dev

Range

N

Mean

St Dev

Range

Adapted SSLI

17

14.5

4.1

9–24

16

15.5

5.2

6–24

ECAS – Section B

17

1.2

1.1

0–4

16

1.1

1.0

0–3

GAD-7

17

8.7

5.7

0–21

16

6.6

4.2

0–15

PHQ-9

17

10.2

5.9

11–24

16

8.9

5.8

2–21

QOLLTI-F v2

17

5.8

0.8

4.5–7.0

15

5.8

0.7

4.6–5.8

Relationship Closeness Scale

17

16.4

2.0

13–20

16

17.1

2.1

14–20

ZBI

17

41.5

13.4

23–70

16

38.6

12.3

24–60

  1. ALSFRS-R Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, ECAS Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen, GAD-7 Generalized Anxiety Disorder 7-Item, MQOL-R McGill Quality of Life Questionnaire-Revised, PHQ-9 Patient Health Questionnaire-9, QOLLTI-F v2 Quality of Life in Life-Threatening Illness-Family Carer Version 2, SSLI Social Support List of Interactions, ZBI Zarit Burden Interview